Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies.

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor macrophage (CAR-M) therapy is a novel approach for solid tumors, leveraging macrophages' tumor-homing and phagocytic abilities.
• CAR-M aims to address limitations of CAR-T therapy in solid tumors, including poor infiltration and immunosuppression within the tumor microenvironment (TME).
• First-generation CAR-M constructs have shown modest clinical outcomes due to limited in vivo persistence and effector functions.

Purpose of the Study:

• To review challenges limiting CAR-M efficacy and clinical application.
• To discuss engineering strategies for enhancing CAR-M anti-tumor activity.
• To explore combination therapies and next-generation CAR-M platforms.

Main Methods:

• Review of current literature on CAR-M therapy.
• Analysis of CAR molecular structure optimization strategies.
• Discussion of synergistic mechanisms in combined therapeutic modalities.
• Overview of emerging CAR-M platforms like in vivo edited CAR-M and CAR-monocytes.

Main Results:

• Engineering CAR-M constructs can enhance anti-tumor activity.
• Combining CAR-M with other therapies offers synergistic benefits.
• Next-generation platforms aim to simplify manufacturing and reduce costs.
• Despite challenges, technological innovation is advancing CAR-M translation.

Conclusions:

• CAR-M therapy presents a promising strategy for solid tumor immunotherapy.
• Optimization of CAR structure and combination therapies are key to improving efficacy.
• Next-generation CAR-M platforms hold potential for broader clinical application.
• Continued innovation is crucial for overcoming manufacturing, durability, and safety challenges in CAR-M therapy.